The company has successfully generated a broad pipeline of drug candidates including programs addressing cancer, neurology, inflammation, infectious disease and metabolic disease that are advancing toward investigational new drug (IND) filings.

This information, when paired with the company’s breadth of in-house drug discovery and development expertise, drives the identification of novel compounds designed to most effectively address significant unmet medical needs for clinically meaningful disease subtypes. The company’s SMarTR ™ Engine, which leverages machine learning, advanced analytics and mathematics in an AI framework, and its CTSeek ™ liquid biopsy diagnostic technology, generate insights from molecular data for a deep understanding of disease biology and patient subtypes. The company is working to redefine precision medicine by combining a sophisticated, proprietary predictive computational platform with traditional pharmaceutical industry experience. To request a meeting with Auransa at the China Healthcare Summit 2018, please contact Andrew Wong, Auransa’s senior vice president of corporate business development at, or Stephanie Diaz of Vida Strategic Partners at Auransaįounded in 2014, Auransa is an artificial intelligence (AI)-driven pharmaceutical company developing precision medicines in areas of significant unmet medical need. Lum will be joined by members of the Auransa management team to provide introductions to Auransa and how the company is combining its proprietary SMarTR ™ Engine, a powerful predictive platform, with broad drug discovery and development expertise, to redefine precision medicine. Tony Zhang, Founder and CEO, LinkDoc Technology (Beijing) Co.Īlex Zhavoronkov, Ph.D., Co-founder and CEO, Insilico MedicineĪdditionally, Dr. Stanley Li, M.D., Founder, DXY (Session Chair)Īndrea de Souza, Senior Director, Informatics, Eli Lilly (Moderator)Ĭhengming GU, M.D., VP, Medical Affairs, Greater China Region, Pfizer Pek Lum, Ph.D., Co-founder and CEO, Auransa Additionally, company management will take part in 1-on-1 meetings at the conference, which is being held November 13-14 in Shanghai, China.ĭetails of the roundtable panel discussion are as follows: Session Title:Ĭhina’s Globalization Challenge: Leveraging Its AI Future Pek Lum, Ph.D., the company’s co-founder and chief executive officer, will participate in a roundtable panel discussion examining the potential for the China healthcare industry to successfully leverage AI to build global digital health companies. 06, 2018 (GLOBE NEWSWIRE) - Auransa, Inc., an artificial intelligence (AI)-driven pharmaceutical company developing precision medicines in areas of significant unmet medical need, today announced the company’s participation at the upcoming BioCentury-BayHelix China Healthcare Summit 2018. In May, Reuters reported that Beijing was pressing audio platform Ximalaya to drop US listing plans and opt for Hong Kong instead, with one source at the time citing Beijing's concerns that US regulators will potentially gain more access to audit documents of New York-listed Chinese companies.Īnalysts also note the tougher stance coincides with new US regulations being rolled out that could see Chinese companies delisted if they do not comply with US auditing rules.PALO ALTO, Calif., Nov. The tougher stance by the Cybersecurity Administration of China has been driven in part by concerns that the United States could gain greater access to data owned by Chinese firms - similar to concerns that the previous Trump administration had voiced about Chinese firms operating in the United States. So far this year, a record $12.5 billion by Chinese firms has been raised from 34 US listings, Refinitiv data shows, well up from the $1.9 billion from 14 deals in the same period a year ago.Įight Chinese companies including home service platform Daojia Ltd and Atour Lifestyle Holdings have made public filings with the Securities and Exchange Commission (SEC) to list in the US later this year, a review of the filings showed. US capital markets have been a lucrative source of funding for Chinese firms in the past decade, especially for technology companies looking to benchmark their valuations against listed peers there and tap an abundant liquidity pool. The issue, then, is how tech startups should strike a balance between aiming too high and taking a faster route. Morgan Stanley and Bank of America declined to comment, while CICC did not respond to a Reuters request for comment. Morgan Stanley, Bank of America, and China International Capital Corp Ltd (CICC) were the investment banks on the deal. LinkDoc did not immediately respond to a request for comment. The sources declined to be identified as the information has not yet been made public. The book closed one day earlier than planned on Wednesday, one of the three sources and a separate person said.

It had planned to sell 10.8 million shares between $17.50 and $19.50 each.

Linkdoc technology ltd